Put Our Expertise
to Work for You
The number of therapeutic discovery projects on which our team has worked is in the hundreds, yielding dozens of clinical stage projects and multiple drugs on the market.
Now you can access our expertise to produce large panels of sequence- and epitope-diverse, high-affinity monoclonal antibodies against a broad variety of target types, including membrane multi-spanners and targets with high sequence conservation between mouse and human.
Our expertise in functional assay design and execution then helps ensure that screening assays identify the better lead candidate antibodies earlier in the screening process. We recover and sequence the full VH and VL region cDNAs of your selected leads, provide further analyses of the sequences, then scale-up and provide purification of recombinant fully human antibodies.
What It Is Like to Work with Us
Entrusting your antibody discovery project to an external partner is a critical decision. Every discovery project is unique. We will work with you to design a discovery campaign tailored to the needs of your project.
We understand what is at stake because we have led therapeutic discovery projects ourselves. Our engagement with you will be guided by tenets of good science, urgency, accountability and responsibility, focused on discovery of the best therapeutic lead candidate antibodies. We are committed to the success of your project.
We will conduct the work on your project at our facility in San Diego, California, with some work, such as sequencing or high-resolution kinetic analyses, performed by vendors we know and trust in the United States.
Meet Your Team
Dana brings a combined twelve years of experience in therapeutic antibody development at both large and small biopharmaceutical companies. Dana was a founding member of the Ablexis research group responsible for creating the data package for validating the AlivaMab Mouse. He was instrumental in the execution of the recovery and screening workflows that yielded therapeutic-quality AlivaMab antibodies.
Dana was part of the hybridoma group at Pfizer, Inc. in the metabolic disease group at Pfizer CovX and a member of Pfizer Exploratory Technologies exploring cancer stem cells. At Igenica, Inc., Dana was a founding member of the hybridoma group, establishing the hybridoma platform and assay screening methods for generating their therapeutic antibody candidates. Dana served as a scientist in the antibody discovery group at NGM Biopharmaceuticals, Inc., where he worked on diverse targets utilizing the latest tools, methods and technologies available in antibody development.
Dana received his B.S. in pharmacology from the University of California, Santa Barbara.
James has twenty-five years of operations management experience spanning a range of technical industries and applications from nuclear-powered propulsion systems and industrial chemical processing to biological research laboratories. Additionally, James has fifteen years of protein engineering and bioprocessing experience focused on recombinant antibodies for drug screening and development.
James joined Sevion Therapeutics as Chief Technology Officer in 2014 upon the merger of Fabrus and Senesco, where he was responsible for managing the corporate and research operations for a publicly-traded company as well as mammalian cell line development and recombinant protein production. Prior to his time a Sevion, he managed corporate and research operations for Fabrus starting in 2007 as the Chief Operating Officer and co-founder.
James received his Ph.D. from The Scripps Research Institute working jointly with the Genomics Institute of the Novartis Research Foundation and was a staff scientist at Kythera Biopharmaceuticals, Inc. Prior to receiving his doctorate, James was a qualified and decorated nuclear propulsion plant mechanic and work center supervisor in the U.S. Navy on board both USS Enterprise and USS Texas.
Jacek brings more than fourteen years of experience largely focused on protein chemistry and therapeutic antibody discovery and development to his role as the Associate Director of Protein Sciences. He has broad and deep experience in the analytical characterization of antibodies in addition to expression and purification. Jacek has led antibody drug conjugate programs investigating new chemistries and new payloads with lower off target toxicities. He has directed development programs assessing the developability and formulation in therapeutic antibodies including the initiation and direction of cGMP manufacturing campaigns.
Jacek comes to AlivaMab having helped launch early-stage biotechnology and biotherapeutic companies such as Phanes Therapeutics, MabVax Therapeutices, Sevion Therapeutics, and Chimeros. Jacek received his BS in chemistry from Saint Mary’s College of California and his Ph.D. in material chemistry from the University of California Santa Barbara.
Maya has more than 20 years of experience in drug development and medical devices, holding positions of increasing responsibility across multiple functions including business development, alliance management, licensing, program management and quality. Maya is responsible for the company's business development and licensing programs. Prior to joining AlivaMab Discovery Services, she was at Sommetrics, Inc., Leica Biosystems and Kirin Pharma USA in positions where she played a key role in identifying and managing strategic alliances and partnerships. Maya earned her BS in Biochemistry from the University of California at Berkeley.
Ritsuko has more than fifteen years of experience in discovery and development of therapeutic human monoclonal antibodies including expression, validation, affinity maturation and cell line development.
Prior to joining AlivaMab Discovery Services, Ritsuko led the antibody discovery team at MabVax Therapeutics, where she established the anti-tumor associated carbohydrate antigen (TACA) mAb discovery platform using B cells derived from vaccinated cancer patients and identified lead drug candidates. As a staff scientist at Avanir Pharmaceuticals, she oversaw the antibody group and improved the human mAb generation platform using SCID mice against infectious disease targets.
Ritsuko received her Ph.D. in Molecular and Cellular Biology from the Ochanomizu University in Tokyo and did postdoctoral research at the University of California at San Diego.